CA2309395A1 - Methodes de prevention et de traitement de la maladie d'alzheimer - Google Patents

Methodes de prevention et de traitement de la maladie d'alzheimer Download PDF

Info

Publication number: CA2309395A1
Authority: CA; Canada
Prior art keywords: fsh; agent; disease; gnrh; antibodies
Prior art date: 1999-06-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002309395A

Other languages

English (en)

Inventor

Richard Lloyd Bowen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Voyager Pharmaceutical Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-04

Filing date

2000-05-24

Publication date

2000-12-04

1999-06-04 Priority claimed from US09/326,180 external-priority patent/US6242421B1/en

2000-05-24 Application filed by Individual filed Critical Individual

2000-12-04 Publication of CA2309395A1 publication Critical patent/CA2309395A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 23
208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 17
210000002966 serum Anatomy 0.000 claims abstract description 8
230000001076 estrogenic effect Effects 0.000 claims abstract description 4
230000001548 androgenic effect Effects 0.000 claims abstract description 3
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 33
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 22
239000003795 chemical substances by application Substances 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 16
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 15
239000000893 inhibin Substances 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 10
108010000817 Leuprolide Proteins 0.000 claims description 8
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 8
229960004338 leuprorelin Drugs 0.000 claims description 8
229960005486 vaccine Drugs 0.000 claims description 8
108010069236 Goserelin Proteins 0.000 claims description 7
230000003637 steroidlike Effects 0.000 claims description 4
238000010254 subcutaneous injection Methods 0.000 claims description 4
239000007929 subcutaneous injection Substances 0.000 claims description 4
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
230000001195 anabolic effect Effects 0.000 claims description 3
229960002913 goserelin Drugs 0.000 claims description 3
238000010255 intramuscular injection Methods 0.000 claims description 3
239000007927 intramuscular injection Substances 0.000 claims description 3
108010037003 Buserelin Proteins 0.000 claims description 2
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 2
108010021717 Nafarelin Proteins 0.000 claims description 2
229960002719 buserelin Drugs 0.000 claims description 2
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
229960005408 deslorelin Drugs 0.000 claims description 2
108700025485 deslorelin Proteins 0.000 claims description 2
108700020746 histrelin Proteins 0.000 claims description 2
229960002193 histrelin Drugs 0.000 claims description 2
HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 2
229960002333 nafarelin Drugs 0.000 claims description 2
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 2
238000013268 sustained release Methods 0.000 claims 1
239000012730 sustained-release form Substances 0.000 claims 1
238000012360 testing method Methods 0.000 abstract description 4
239000003263 anabolic agent Substances 0.000 abstract description 2
229940124325 anabolic agent Drugs 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
201000010099 disease Diseases 0.000 description 32
150000001875 compounds Chemical class 0.000 description 18
210000004556 brain Anatomy 0.000 description 14
229940088597 hormone Drugs 0.000 description 14
239000005556 hormone Substances 0.000 description 14
208000035475 disorder Diseases 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
238000003745 diagnosis Methods 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
230000009467 reduction Effects 0.000 description 5
241000282412 Homo Species 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
229960003690 goserelin acetate Drugs 0.000 description 4
238000002483 medication Methods 0.000 description 4
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102100029470 Apolipoprotein E Human genes 0.000 description 3
201000010374 Down Syndrome Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
208000027626 Neurocognitive disease Diseases 0.000 description 3
206010044688 Trisomy 21 Diseases 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
238000003759 clinical diagnosis Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
238000003325 tomography Methods 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
108010025628 Apolipoproteins E Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
241000283086 Equidae Species 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
159000000021 acetate salts Chemical class 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000000556 agonist Substances 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
239000000544 cholinesterase inhibitor Substances 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000002682 neurofibrillary tangle Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
229930182840 (S)-nicotine Natural products 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
108010060159 Apolipoprotein E4 Proteins 0.000 description 1
102100023995 Beta-nerve growth factor Human genes 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
208000032862 Clinical Deterioration Diseases 0.000 description 1
102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
125000000249 D-isoleucyl group Chemical group N[C@@H](C(=O)*)[C@@H](CC)C 0.000 description 1
125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 description 1
125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000026097 Factitious disease Diseases 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
229940087098 Oxidase inhibitor Drugs 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
206010052276 Pseudodementia Diseases 0.000 description 1
IGMKTIJBFUMVIN-UHFFFAOYSA-N Sabeluzole Chemical compound N=1C2=CC=CC=C2SC=1N(C)C(CC1)CCN1CC(O)COC1=CC=C(F)C=C1 IGMKTIJBFUMVIN-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical class O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940070021 anabolic steroids Drugs 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000006741 behavioral dysfunction Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229960003135 donepezil hydrochloride Drugs 0.000 description 1
XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
229940094892 gonadotropins Drugs 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003933 intellectual function Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000036244 malformation Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004630 mental health Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
238000010984 neurological examination Methods 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000003863 physical function Effects 0.000 description 1
238000002600 positron emission tomography Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229960002934 propentofylline Drugs 0.000 description 1
230000005997 psychological dysfunction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
229950008900 sabeluzole Drugs 0.000 description 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
229960003565 tacrine hydrochloride Drugs 0.000 description 1
102000013498 tau Proteins Human genes 0.000 description 1
108010026424 tau Proteins Proteins 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002309395A 1999-06-04 2000-05-24 Methodes de prevention et de traitement de la maladie d'alzheimer Abandoned CA2309395A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/326,180 US6242421B1 (en)	1997-11-06	1999-06-04	Methods for preventing and treating Alzheimer's disease
US09/326,180		1999-06-04

Publications (1)

Publication Number	Publication Date
CA2309395A1 true CA2309395A1 (fr)	2000-12-04

Family

ID=23271130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002309395A Abandoned CA2309395A1 (fr)	1999-06-04	2000-05-24	Methodes de prevention et de traitement de la maladie d'alzheimer

Country Status (1)

Country	Link
CA (1)	CA2309395A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002102401A1 (fr) *	2001-04-30	2002-12-27	Zentaris Gmbh	Traitement de la demence et de maladies neurodegeneratives par des doses intermediaires d'antagonistes de luteoluberine
WO2008077027A3 (fr) *	2006-12-18	2008-10-16	Univ Case Western Reserve	Traitement de troubles cognitifs post-ménopausiques ou post-hystérectomie
KR100878137B1 (ko) *	2002-12-17	2009-01-14	엠디알엔에이, 인코포레이티드	Ｙ2 수용체-결합 펩티드들의 강화된 점막 전달용 혼합물과방법 및 비만 예방과 치료를 위한 방법
WO2009046835A1 (fr) *	2007-09-11	2009-04-16	Mondobiotech Laboratories Ag	Utilisation de goséréline et d'amyline en tant qu'agents thérapeutiques
WO2009046877A3 (fr) *	2007-09-11	2009-05-28	Mondobiotech Lab Ag	Utilisation d'un peptide en tant qu'agent thérapeutique

2000
- 2000-05-24 CA CA002309395A patent/CA2309395A1/fr not_active Abandoned

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002102401A1 (fr) *	2001-04-30	2002-12-27	Zentaris Gmbh	Traitement de la demence et de maladies neurodegeneratives par des doses intermediaires d'antagonistes de luteoluberine
US7288517B2 (en)	2001-04-30	2007-10-30	Aeterna Zentaris Gmbh	Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
RU2319501C2 (ru) *	2001-04-30	2008-03-20	Центарис Гмбх	Способ лечения болезни альцгеймера
KR100878137B1 (ko) *	2002-12-17	2009-01-14	엠디알엔에이, 인코포레이티드	Ｙ2 수용체-결합 펩티드들의 강화된 점막 전달용 혼합물과방법 및 비만 예방과 치료를 위한 방법
WO2008077027A3 (fr) *	2006-12-18	2008-10-16	Univ Case Western Reserve	Traitement de troubles cognitifs post-ménopausiques ou post-hystérectomie
WO2009046835A1 (fr) *	2007-09-11	2009-04-16	Mondobiotech Laboratories Ag	Utilisation de goséréline et d'amyline en tant qu'agents thérapeutiques
WO2009046877A3 (fr) *	2007-09-11	2009-05-28	Mondobiotech Lab Ag	Utilisation d'un peptide en tant qu'agent thérapeutique

Publication	Publication Date	Title
US6242421B1 (en)	2001-06-05	Methods for preventing and treating Alzheimer's disease
Milner et al.	1979	Experience with human growth hormone in Great Britain: the report of the MRC Working Party
Pickar et al.	1984	Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
EA021303B1 (ru)	2015-05-29	Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
US12138254B2 (en)	2024-11-12	Chronic nightly dosing of lasmiditan for migraine prevention
US9867816B2 (en)	2018-01-16	PPARγ agonists for treatment of multiple sclerosis
US12318380B2 (en)	2025-06-03	Treatment of demyelinating diseases
AU2021200093B2 (en)	2024-03-07	Treatment and prevention of alzheimer's disease (ad)
Evoli et al.	1996	A practical guide to the recognition and management of myasthenia gravis
US20190276560A1 (en)	2019-09-12	Composition and method for treating alzheimer's disease
US20120237472A1 (en)	2012-09-20	Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
CA2309395A1 (fr)	2000-12-04	Methodes de prevention et de traitement de la maladie d'alzheimer
US20190247394A1 (en)	2019-08-15	Methods of treating developmental syndromes with pde10a inhibitors
CN106659738B (zh)	2021-02-09	阿尔茨海默病(ad)的治疗和预防
Cignarelli et al.	2005	A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex
US20210023074A1 (en)	2021-01-28	Treatment of demyelinating diseases
JP6416213B2 (ja)	2018-10-31	気分障害患者の治療のためのナルメフェン
WO2025124760A1 (fr)	2025-06-19	Traitement de la sous-population de patients atteints de polyarthrite rhumatoïde
US20140128412A1 (en)	2014-05-08	Combination of an antipsychotic and an anti-inflammatory agent
CN118804754A (zh)	2024-10-18	利用替拉扎德盐治疗和预防疾病的组合物和方法
Shea	2008	From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap
Cutler et al.	1986	Alzheimer's disease: clinical, neuropathologic, neuropsychologic, and brain metabolic findings
Viegas et al.	2007	The pathogenesis of myasthenic syndromes: A practical guide to diagnosis and management
Henr et al.	1998	Clinical changes and brain drug concentrations on the third day of substitution of placebo for SSRI treatment
Porru et al.	2012	Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome

Legal Events

Date	Code	Title	Description
2003-11-13	EEER	Examination request
2014-07-21	FZDE	Dead	Effective date: 20140526